Key Insights

Highlights

Success Rate

87% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.8%

2 terminated out of 42 trials

Success Rate

86.7%

+0.2% vs benchmark

Late-Stage Pipeline

7%

3 trials in Phase 3/4

Results Transparency

23%

3 of 13 completed with results

Key Signals

3 with results87% success

Data Visualizations

Phase Distribution

27Total
Not Applicable (24)
P 4 (3)

Trial Status

Completed13
Recruiting9
Unknown8
Active Not Recruiting4
Not Yet Recruiting3
Terminated2

Trial Success Rate

86.7%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (42)

Showing 20 of 20 trials
NCT07197736Recruiting

DELINEATE-Prospective

NCT06608823Not ApplicableRecruitingPrimary

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

NCT06594705Not ApplicableRecruitingPrimary

The JenaValve ALIGN-AR LVAD Registry

NCT03383445Not ApplicableActive Not Recruiting

Transcatheter Aortic Valve Replacement Versu Surgical Aortix Valve Replacement for Treating Elderly Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Prospective Randomized Study The VIVA Trial

NCT07453407Not ApplicableRecruitingPrimary

ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy

NCT07458672Not ApplicableNot Yet RecruitingPrimary

TAVR for Aortic Regurgitation Under TTE Guidance

NCT07453849Not ApplicableNot Yet RecruitingPrimary

TAVR for Aortic Regurgitation Under TEE Guidance

NCT07398911Not ApplicableEnrolling By InvitationPrimary

3-Dimensional Simulation Guided Transcatheter Aortic Valve Replacement in Aortic Regurgitation(DIGITAL)

NCT06818084Phase 4Recruiting

TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System

NCT04126018Recruiting

Comparative Imaging Assessment of Valvular Heart Disease

NCT06780241RecruitingPrimary

Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease

NCT03466918Not ApplicableCompleted

China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population

NCT05714293Not ApplicableEnrolling By Invitation

CT-evaluation of Coronary Ostia Height After Surgical Aortic Valve Replacement.

NCT07104968Not Yet RecruitingPrimary

Mild and Moderate Aortic Regurgitation: Risk Factors for Progress and Outcome

NCT07097740Not ApplicableRecruiting

Early Feasibility Study of Surgical Implantation of a Polymer Prosthetic Mitral and Aortic Valve

NCT06034028Not ApplicableActive Not Recruiting

J-Valve TF Early Feasibility Study

NCT06751368Completed

The Fate of Aortic Valve After SAS Surgery in Children

NCT06101888Not ApplicableRecruitingPrimary

Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)

NCT03314857Not ApplicableCompleted

China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population

NCT05515848Completed

Aortic Valve-sparing Root Replacement, According to the Inclusion Technique Described by Tirone David

Scroll to load more

Research Network

Activity Timeline